High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria
Critical Care2014Vol. 18(3), pp. R90–R90
Citations Over TimeTop 10% of 2014 papers
Gennaro De Pascale, Luca Montini, Mariano Alberto Pennisi, Valentina Bernini, Riccardo Maviglia, Giuseppe Bello, Teresa Spanu, Mario Tumbarello, Massimo Antonelli
Abstract
TGC was well tolerated at a higher than standard dose in a cohort of critically ill patients with severe infections. In the VAP subgroup the high-dose regimen was associated with better outcomes than conventional administration due to Gram-negative MDR bacteria.
Related Papers
- → Molecular Epidemiology and Mechanisms of Tigecycline Resistance in Clinical Isolates of Acinetobacter baumannii from a Chinese University Hospital(2013)173 cited
- → Over expression of AdeABC and AcrAB-TolC efflux systems confers tigecycline resistance in clinical isolates of Acinetobacter baumannii and Klebsiella pneumoniae(2016)35 cited
- → In Vitro Activity of Tigecycline and Colistin against clinical isolates of Acinetobacter baumannii in Hospitals in Tehran and Bandar-Abbas, Iran.(2015)13 cited
- → Synergistic Role of Biofilm-Associated Genes and Efflux Pump Genes in Tigecycline Resistance of Acinetobacter baumannii(2023)5 cited
- → Clinical and laboratory responses to tigecycline in children(2022)1 cited